ATE141506T1 - Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff - Google Patents

Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff

Info

Publication number
ATE141506T1
ATE141506T1 AT91915614T AT91915614T ATE141506T1 AT E141506 T1 ATE141506 T1 AT E141506T1 AT 91915614 T AT91915614 T AT 91915614T AT 91915614 T AT91915614 T AT 91915614T AT E141506 T1 ATE141506 T1 AT E141506T1
Authority
AT
Austria
Prior art keywords
antineoplastic
effect
potentiating
antineoplastic effect
enhancement
Prior art date
Application number
AT91915614T
Other languages
English (en)
Inventor
Junji Uchida
Hiroyuki Okabe
Teiji Takechi
Setsuo Takeda
Yuji Yamada
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17034249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE141506(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE141506T1 publication Critical patent/ATE141506T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT91915614T 1990-09-07 1991-09-05 Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff ATE141506T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP23871990 1990-09-07

Publications (1)

Publication Number Publication Date
ATE141506T1 true ATE141506T1 (de) 1996-09-15

Family

ID=17034249

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91915614T ATE141506T1 (de) 1990-09-07 1991-09-05 Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff

Country Status (14)

Country Link
EP (1) EP0500953B1 (de)
JP (1) JP2557303B2 (de)
KR (1) KR0146952B1 (de)
AT (1) ATE141506T1 (de)
AU (1) AU644684B2 (de)
CA (1) CA2071819A1 (de)
DE (2) DE69121551T2 (de)
DK (1) DK0500953T3 (de)
ES (1) ES2091941T3 (de)
GR (1) GR3021003T3 (de)
HU (1) HU211739A9 (de)
LU (1) LU90791I2 (de)
NL (1) NL300041I2 (de)
WO (1) WO1992004028A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05310573A (ja) * 1992-05-01 1993-11-22 Dotsuto:Kk リウマチ治療薬
US5643191A (en) * 1995-01-26 1997-07-01 Sorin Biomedical Inc. Cardioplegia delivery system and method for converting from warm cardioplegia to cold cardioplegia
US5702358A (en) * 1995-02-23 1997-12-30 Sorin Biomedical Inc. Cardioplegia delivery apparatus and method of use
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US6538001B1 (en) * 1998-10-12 2003-03-25 Nikolai Borisovich Leonidov Crystalline modification of 5-fluoro-1-(tetrahydro-2-furyl) uracil and complex compounds based thereon, producing antineoplastic effect
NZ542150A (en) 2003-03-14 2009-09-25 Taiho Pharmaceutical Co Ltd Antitumor effect potentiator and antitumor agent
TWI468188B (zh) 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
WO2009139085A1 (ja) 2008-05-12 2009-11-19 静岡県 抗腫瘍剤、キット及び癌治療方法
KR102258514B1 (ko) * 2019-09-23 2021-05-31 연세대학교 산학협력단 신규한 다층형 좌약 제제

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5953885B2 (ja) * 1978-02-10 1984-12-27 大鵬薬品工業株式会社 抗腫瘍剤組成物
GB2016921B (en) * 1978-03-27 1982-08-18 Taiho Pharmaceutical Co Ltd Anti cancer compositions containing uracil derivatives
JPS5780319A (en) * 1980-11-06 1982-05-19 Taiho Yakuhin Kogyo Kk Anti-tumor agent having reduced toxicity
JPS5838210A (ja) * 1981-08-31 1983-03-05 Taiho Yakuhin Kogyo Kk 直腸投与用製剤

Also Published As

Publication number Publication date
JP2557303B2 (ja) 1996-11-27
DE10299023I1 (de) 2003-06-05
KR0146952B1 (ko) 1998-08-17
ES2091941T3 (es) 1996-11-16
HU211739A9 (en) 1995-12-28
GR3021003T3 (en) 1996-12-31
DE10299023I2 (de) 2010-05-06
WO1992004028A1 (fr) 1992-03-19
LU90791I2 (fr) 2001-10-08
DE69121551T2 (de) 1997-01-02
AU644684B2 (en) 1993-12-16
KR927002224A (ko) 1992-09-03
DE69121551D1 (de) 1996-09-26
EP0500953B1 (de) 1996-08-21
EP0500953A1 (de) 1992-09-02
NL300041I2 (nl) 2002-02-01
CA2071819A1 (en) 1992-03-08
AU8447991A (en) 1992-03-30
EP0500953A4 (en) 1993-04-21
DK0500953T3 (da) 1997-01-06
NL300041I1 (nl) 2001-06-01

Similar Documents

Publication Publication Date Title
NL970006I2 (nl) Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson.
MX9707453A (es) Derivados de quinazolina.
DE69318031D1 (de) Ematiomerenreine beta-d-dioxolane nucleoside mit selektiver antihepatitis b-virus wirkung
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
KR910019618A (ko) 발기부전증 치료용 제약 조성물
ATE173627T1 (de) Medizinische zusammensetzung
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
ATE141506T1 (de) Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff
DE3875769D1 (de) Therapeutische nukleoside.
DK0476066T3 (da) Antiviralt præparat indeholdende 3-azido-2,3-dideoxy-5-methylcytidin
BG100599A (en) Antiviral form and therapeutical method
MY104521A (en) Treatment of depression.
KR910015300A (ko) 부스피론 : 수면 무호흡증의 치료용도
DE69019404D1 (de) Derivate von Penciclovir zur Behandlung von Hepatitis-B-Infektionen.
DE69103773D1 (de) Derivate von hydroxaminsäure die lipoxygenase hemmen.
SE8804640D0 (sv) Medicament comprising cyclolinopeptide a
ATE210445T1 (de) Verwendung von 2-aminopurinderivaten zur behandlung und prophylaxe der menschlichen herpesvirus 7 infektionen
GB2019720A (en) S-adenosyl-L-homocysteine and salts thereof for use in therapy
KR900016130A (ko) 2-피리딜메틸티오 유도체 및 궤양 치료제
KR890007737A (ko) 진토작용을 하는 약제
ES2062752T3 (es) Preparado de una sal de oxipurinol en forma oral para el tratamiento de hiperuricemia.
DE69228945D1 (de) Pharmazeutische pentapeptid-zusammensetzung und ihre verwendung
IT1243368B (it) Uso del bendazac e dei suoi sali farmaceuticamente accettabili